Abstract
Multiple myeloma (MM) invariably develops in the bone marrow (BM), indicating the strong requirement of this tumor for the peculiar BM microenvironment, rich in cytokine and hematopoietic precursor cells. Interleukin-6 (IL-6) and a proliferation inducing ligand (APRIL) are key cytokines implicated in MM development. Here, we show that MM cells changed the hematopoietic microenvironment early upon BM infiltration by strongly downregulating hematopoietic precursor cells from all lineages except myeloid precursor cells. Myeloid precursor cells constituted a major source of APRIL in MM-infiltrated BM, and their proliferative response to IL-6 upregulation explained their relative resistance to MM infiltration. The osteolytic molecule receptor activator of NF-kB ligand (RANK-L) expressed by MM cells started this myeloid proliferation by inducing in a contact-dependent manner IL-6 production by myeloid precursor cells themselves. Taken together, our data demonstrate that MM cells do not simply displace hematopoietic cells upon BM infiltration, but rather selectively modulate the BM microenvironment to preserve a pool of high APRIL-producing myeloid precursor cells. Our data also identify a positive regulation of APRIL by IL-6 in myeloid precursor cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Schneider P . The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005; 17: 282–289.
Matthes T, McKee T, Dunand-Sauthier I, Manfroi B, Park S, Passweg J et al. Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrative bone marrow. Leukemia 2015; e-pub ahead of print 10 March 2015; 10.1038/leu.2015.68.
Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148–3157.
Matthes T, Dunand-Sauthier I, Santiago-Raber ML, Krause KH, Donze O, Passweg J et al. Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood 2011; 118: 1838–1844.
Borregaard N . Neutrophils, from marrow to microbes. Immunity 33: 657–670.
Podar K, Chauhan D, Anderson KC . Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009; 23: 10–24.
Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83–85.
Klein B, Zhang XG, Lu ZY, Bataille R . Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863–872.
Jourdan M, Veyrune JL, De Vos J, Redal N, Couderc G, Klein B . A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 2003; 22: 2950–2959.
Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000; 275: 27845–27850.
van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, van der Lelie J et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol 1998; 102: 783–790.
San-Miguel J, Blade J, Shpilberg O, Grosicki S, Maloisel F, Min CK et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 2014; 123: 4136–4142.
Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517–526.
Rosean TR, Tompkins VS, Olivier AK, Sompallae R, Norian LA, Morse HC 3rd et al. The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice. Leukemia 2014; 29: 233–237.
Hofgaard PO, Jodal HC, Bommert K, Huard B, Caers J, Carlsen H et al. A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One 2012; 7: e51892.
Preynat-Seauve O, Contassot E, Schuler P, Piguet V, French LE, Huard B . Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process. Cancer Res 2007; 67: 5009–5016.
Biermann H, Pietz B, Dreier R, Schmid KW, Sorg C, Sunderkotter C . Murine leukocytes with ring-shaped nuclei include granulocytes, monocytes, and their precursors. J Leukoc Biol 1999; 65: 217–231.
Maeda K, Malykhin A, Teague-Weber BN, Sun XH, Farris AD, Coggeshall KM . Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals. Blood 2009; 113: 4534–4540.
Welniak LA, Karas M, Yakar S, Anver MR, Murphy WJ, LeRoith D . Effects of organ-specific loss of insulin-like growth factor-I production on murine hematopoiesis. Biol Blood Marrow Transplant 2004; 10: 32–39.
Berardi AC, Wang A, Abraham J, Scadden DT . Basic fibroblast growth factor mediates its effects on committed myeloid progenitors by direct action and has no effect on hematopoietic stem cells. Blood 1995; 86: 2123–2129.
Johnson CS, Keckler DJ, Topper MI, Braunschweiger PG, Furmanski P . In vivo hematopoietic effects of recombinant interleukin-1 alpha in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 1989; 73: 678–683.
Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92: 4150–4166.
Dybedal I, Bryder D, Fossum A, Rusten LS, Jacobsen SE . Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells. Blood 2001; 98: 1782–1791.
Broxmeyer HE, Cooper S, Kohli L, Hangoc G, Lee Y, Mantel C et al. Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol 2003; 170: 421–429.
Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC . Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82: 3712–3720.
Lai FP, Cole-Sinclair M, Cheng WJ, Quinn JM, Gillespie MT, Sentry JW et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 2004; 126: 192–201.
Josien R, Wong BR, Li HL, Steinman RM, Choi Y . TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999; 162: 2562–2568.
van Zaanen HC, Koopmans RP, Aarden LA, Rensink HJ, Stouthard JM, Warnaar SO et al. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest 1996; 98: 1441–1448.
Karadag A, Oyajobi BO, Apperley JF, Russell RG, Croucher PI . Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts. Br J Haematol 2000; 108: 383–390.
Lokhorst HM, Lamme T, de Smet M, Klein S, de Weger RA, van Oers R et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994; 84: 2269–2277.
Portier M, Rajzbaum G, Zhang XG, Attal M, Rusalen C, Wijdenes J et al. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol 1991; 21: 1759–1762.
Wong D, Winter O, Hartig C, Siebels S, Szyska M, Tiburzy B et al. Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches. PLoS One 2014; 9: e109018.
de Vries TJ, Schoenmaker T, Hooibrink B, Leenen PJ, Everts V . Myeloid blasts are the mouse bone marrow cells prone to differentiate into osteoclasts. J Leukoc Biol 2009; 85: 919–927.
Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999; 190: 1741–1754.
Jagannath S, Kyle RA, Palumbo A, Siegel DS, Cunningham S, Berenson J . The current status and future of multiple myeloma in the clinic. Clin Lymphoma Myeloma Leuk 2010; 10: E1–16.
Acknowledgements
This work was supported by the Henri Dubois Ferrière/Dinu Lipatti Foundation, the Swiss Cancer League, the INSERM and the Grenoble-Alpes University. We thank Patrice Marche for his critical reading of the manuscript.
Author contributions
ID-S, AZ, BM and BH performed experiments. TM and BB provided reagents. TM and BH analyzed data and wrote the manuscript. BH designed the study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Matthes, T., Manfroi, B., Zeller, A. et al. Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow. Leukemia 29, 1882–1890 (2015). https://doi.org/10.1038/leu.2015.145
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.145
This article is cited by
-
Targeting arginase-1 exerts antitumor effects in multiple myeloma and mitigates bortezomib-induced cardiotoxicity
Scientific Reports (2022)
-
Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma
International Journal of Hematology (2016)
-
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
Cellular and Molecular Life Sciences (2016)